MCID: HYP043
MIFTS: 47

Hyperandrogenism

Categories: Endocrine diseases
Data Licensing
For inquiries, contact:

Aliases & Classifications for Hyperandrogenism

MalaCards integrated aliases for Hyperandrogenism:

Name: Hyperandrogenism 11 75 53 43 14 16 71
Hyperandrogenization Syndrome 11

Classifications:



External Ids:

Disease Ontology 11 DOID:11613
MeSH 43 D017588
SNOMED-CT 68 237793004
UMLS 71 C0206081

Summaries for Hyperandrogenism

MalaCards based summary: Hyperandrogenism, also known as hyperandrogenization syndrome, is related to cortisone reductase deficiency 2 and adrenal cortical adenoma. An important gene associated with Hyperandrogenism is INSR (Insulin Receptor), and among its related pathways/superpathways are Metabolism and Diseases of glycosylation. The drugs Topiramate and Ethinylestradiol have been mentioned in the context of this disorder. Affiliated tissues include ovary, skin and pituitary, and related phenotypes are nervous system and growth/size/body region

Wikipedia: 75 Hyperandrogenism is a medical condition characterized by high levels of androgens. It is more common in... more...

Related Diseases for Hyperandrogenism

Diseases related to Hyperandrogenism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 401)
# Related Disease Score Top Affiliating Genes
1 cortisone reductase deficiency 2 32.2 POMC HSD11B1
2 adrenal cortical adenoma 32.0 POMC CYP21A2 CYP17A1 CYP11A1
3 cortisone reductase deficiency 32.0 POMC HSD11B1 CYP21A2 CYP17A1
4 acanthosis nigricans 31.0 SHBG INSR INS IGF1 ADIPOQ
5 alopecia 30.9 SRD5A1 SHBG PRL IGF1 CYP19A1 AR
6 alopecia, androgenetic, 1 30.9 SRD5A1 SHBG CYP21A2 CYP19A1 AR
7 abdominal obesity-metabolic syndrome 1 30.7 INS IGFBP1 HSD11B1 ADIPOQ
8 hyperinsulinism 30.7 SHBG INSR INS IGFBP3 IGFBP1 IGF1
9 acne 30.7 SRD5A1 SHBG PRL POMC INS IGF1
10 androgenic alopecia 30.6 SRD5A1 SHBG PRL INS IGF1 CYP19A1
11 luteoma 30.6 SHBG CYP21A2 CYP19A1
12 adrenal adenoma 30.5 POMC HSD11B1 CYP21A2 CYP17A1 CYP11A1
13 aromatase deficiency 30.5 INS CYP19A1
14 leydig cell tumor 30.5 PRL GNRH1 CYP21A2 CYP19A1 CYP17A1 CYP11A1
15 pituitary-dependent cushing's disease 30.5 PRL POMC
16 hyperprolactinemia 30.4 SHBG PRL POMC INS IGF1 GNRH1
17 ovarian cyst 30.3 SHBG PRL GNRH1 CYP19A1
18 endometrial hyperplasia 30.3 CYP19A1 CYP17A1 AR
19 infertility 30.3 SHBG PRL IGFBP1 GNRH1 CYP21A2 CYP19A1
20 graves disease 1 30.3 SHBG POMC INS
21 fatty liver disease 30.3 INSR INS IGF1 ADIPOQ
22 insulin-like growth factor i 30.3 SHBG PRL INSR INS IGFBP3 IGFBP1
23 leptin deficiency or dysfunction 30.3 POMC INS IGF1 GNRH1 ADIPOQ
24 amenorrhea 30.2 WNT4 SHBG PRL POMC INS IGF1
25 lipid metabolism disorder 30.2 SHBG POMC INSR INS IGF1 HSD11B1
26 hyperglycemia 30.2 INSR INS IGF1 ADIPOQ
27 galactorrhea 30.2 PRL IGF1
28 sleep apnea 30.2 INS IGF1 ADIPOQ
29 apnea, obstructive sleep 30.1 POMC INS IGF1 ADIPOQ
30 congenital generalized lipodystrophy 30.1 INSR INS ADIPOQ
31 anovulation 30.1 SRD5A1 SHBG PRL INS IGFBP3 IGFBP1
32 donohue syndrome 30.1 INSR INS IGF1
33 persistent fetal circulation syndrome 30.1 POMC INS IGF1
34 intracranial hypertension 30.1 PRL POMC HSD11B1
35 intracranial hypertension, idiopathic 30.1 POMC IGF1 HSD11B1
36 estrogen excess 30.1 SHBG PRL GNRH1 CYP19A1
37 turner syndrome 30.0 SHBG INS IGFBP3 IGFBP1 IGF1 CYP21A2
38 precocious puberty, male-limited 30.0 POMC GNRH1 CYP21A2 CYP19A1
39 central precocious puberty 30.0 POMC IGFBP3 IGF1 GNRH1
40 glucose intolerance 30.0 SHBG PRL POMC INSR INS IGFBP1
41 type 2 diabetes mellitus 30.0 SHBG PRL POMC INSR INS IGFBP3
42 pineal hyperplasia, insulin-resistant diabetes mellitus, and somatic abnormalities 30.0 INSR INS IGFBP3 IGF1
43 hyperthyroidism 29.9 SHBG PRL POMC INS IGF1 ADIPOQ
44 hypertrichosis 29.9 SHBG POMC INSR INS
45 endometriosis 29.9 WNT4 IGFBP1 GNRH1 CYP19A1 CYP17A1
46 pre-eclampsia 29.9 SHBG INS IGFBP3 IGFBP1 IGF1 AR
47 adult syndrome 29.9 POMC INS IGF1 ADIPOQ
48 sleep disorder 29.9 POMC INS IGF1 ADIPOQ
49 adrenal carcinoma 29.9 POMC INS HSD3B2 CYP21A2 CYP17A1 CYP11A1
50 multiple endocrine neoplasia, type i 29.9 PRL POMC INS

Graphical network of the top 20 diseases related to Hyperandrogenism:



Diseases related to Hyperandrogenism

Symptoms & Phenotypes for Hyperandrogenism

GenomeRNAi Phenotypes related to Hyperandrogenism according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 no effect GR00402-S-1 10.2 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1
2 no effect GR00402-S-2 10.2 ADIPOQ AR CYP11A1 CYP17A1 CYP19A1 CYP21A2

MGI Mouse Phenotypes related to Hyperandrogenism:

45 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 nervous system MP:0003631 10.37 ADIPOQ AR CYP11A1 CYP19A1 GNRH1 HSD11B1
2 growth/size/body region MP:0005378 10.35 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1
3 liver/biliary system MP:0005370 10.34 ADIPOQ AR CAPN10 CYP11A1 CYP19A1 GNRH1
4 homeostasis/metabolism MP:0005376 10.34 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1
5 endocrine/exocrine gland MP:0005379 10.33 ADIPOQ AR CAPN10 CYP11A1 CYP19A1 GNRH1
6 renal/urinary system MP:0005367 10.25 ADIPOQ AR CAPN10 CYP19A1 GNRH1 IGF1
7 adipose tissue MP:0005375 10.25 ADIPOQ AR CAPN10 CYP17A1 CYP19A1 HSD11B1
8 cellular MP:0005384 10.25 ADIPOQ AR CYP11A1 CYP17A1 CYP19A1 HSD11B1
9 immune system MP:0005387 10.2 ADIPOQ AR CAPN10 CYP11A1 CYP19A1 CYP21A2
10 muscle MP:0005369 10.19 ADIPOQ AR CYP11A1 CYP19A1 HSD11B1 IGF1
11 cardiovascular system MP:0005385 10.18 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1
12 behavior/neurological MP:0005386 10.18 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1
13 reproductive system MP:0005389 10 AR CYP11A1 CYP17A1 CYP19A1 GNRH1 IGF1
14 skeleton MP:0005390 9.9 ADIPOQ AR CAPN10 CYP11A1 CYP17A1 CYP19A1
15 hematopoietic system MP:0005397 9.77 ADIPOQ AR CAPN10 CYP11A1 CYP19A1 CYP21A2
16 integument MP:0010771 9.4 ADIPOQ AR CYP19A1 CYP21A2 GNRH1 HSD11B1

Drugs & Therapeutics for Hyperandrogenism

Drugs for Hyperandrogenism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 115)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Topiramate Approved Phase 4 97240-79-4 5284627
2
Ethinylestradiol Approved Phase 4 57-63-6 5991
3
Cyproterone acetate Approved, Investigational Phase 4 427-51-0 9880
4
Levoleucovorin Approved, Experimental, Investigational Phase 4 68538-85-2, 58-05-9, 73951-54-9 149436 6006
5
Drospirenone Approved Phase 4 67392-87-4 68873
6 Hemostatics Phase 4
7 Cyproterone acetate, ethinyl estradiol drug combination Phase 4
8 Drospirenone and ethinyl estradiol combination Phase 4
9 Anticonvulsants Phase 4
10
Cyproterone Phase 4 2098-66-0 5284537
11 Contraceptives, Oral, Hormonal Phase 4
12 Contraceptives, Oral Phase 4
13 Contraceptive Agents, Male Phase 4
14 Contraceptive Agents Phase 4
15 Calcium, Dietary Phase 4
16 Follicle Stimulating Hormone Phase 4
17
Calcium Nutraceutical Phase 4 7440-70-2 271
18
Sodium citrate Approved, Investigational Phase 3 68-04-2 23431961
19
Clomifene Approved, Investigational Phase 3 911-45-5 2800
20
Doxycycline Approved, Investigational, Vet_approved Phase 3 564-25-0 54671203
21
Citric acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
22
Enclomiphene Investigational Phase 3 15690-57-0 1548953
23 Androgens Phase 3
24 Estrogen Receptor Modulators Phase 3
25 Estrogen Receptor Antagonists Phase 3
26 Estrogen Antagonists Phase 3
27 Zuclomiphene Phase 3
28 Citrate Phase 3
29 Selective Estrogen Receptor Modulators Phase 3
30 Antibiotics, Antitubercular Phase 3
31 Anti-Bacterial Agents Phase 3
32 Anti-Infective Agents Phase 3
33 Antiprotozoal Agents Phase 3
34 Antiparasitic Agents Phase 3
35 Antimalarials Phase 3
36 Matrix Metalloproteinase Inhibitors Phase 3
37
Pioglitazone Approved, Investigational Phase 1, Phase 2 111025-46-8 4829
38
Ibuprofen Approved Phase 2 15687-27-1 3672
39
Methyltestosterone Approved Phase 2 58-18-4 6010
40
Testosterone undecanoate Approved, Investigational Phase 2 5949-44-0 21873174 65157
41
Testosterone enanthate Approved Phase 2 315-37-7 9416
42
Ferrous fumarate Approved Phase 2 141-01-5
43
Norethisterone Approved Phase 2 68-22-4 199472 6230
44
Orlistat Approved, Investigational Phase 2 96829-58-2 3034010
45
Metformin Approved Phase 2 1115-70-4, 657-24-9 4091
46
Inositol Approved, Investigational, Withdrawn Phase 2 87-89-8
47
Pancrelipase Approved, Investigational Phase 2 53608-75-6 8519
48
Flutamide Approved, Investigational Phase 2 13311-84-7 3397
49
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
50
Inulin Approved, Investigational, Nutraceutical Phase 2 9005-80-5 24763

Interventional clinical trials:

(show top 50) (show all 59)
# Name Status NCT ID Phase Drugs
1 The Changes of Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives With Antiandrogenic Activity, Correction by Antioxidants Unknown status NCT02027337 Phase 4 20 mcg ethinylestradiol /3 mg drospirenone;20 mcg ethinylestradiol/3 mg drospirenone and Selmevit;30 mcg ethinylestradiol/3 mg drospirenone;30 mcg ethinylestradiol/3 mg drospirenone and Selmevit;35 mcg ethinylestradiol/2 mg cyproterone;35 mcg ethinylestradiol/2 mg cyproterone and Selmevit
2 Treatment of Obesity With Topiramate in Patients With Polycystic Ovary Syndrome: a Double-blind Placebo-controlled Clinical Trial Unknown status NCT04453306 Phase 4 Topiramate;Placebo
3 Phase IV Study of the Use of Two Preparations of Ethinyl Estradiol and Cyproterone Acetate in Irregular Menstruation of Hyper-androgenic Origin Unknown status NCT01103518 Phase 4 Ethinyl Estradiol + Cyproterone acetate
4 The Cardiovascular Risk Profile Associated With The Polycystic Ovary Syndrome And With Ovulatory Hyperandrogenism, And Its Changes During Treatment With Metformin Or Oral Contraceptives Completed NCT00428311 Phase 4 Metformin;Ethynyl-estradiol plus cyproterone acetate
5 Positive Clinical and Hormonal Effects of Ethinylestradiol Combined With Drospirenone (EE/DRSP) in Women With Polycystic Ovary Syndrome (PCOS): Impact of Body Weight and Relevance to Hyperandrogenism Completed NCT01360996 Phase 4 3 mg DRSP/20 μg EE
6 Ovarian Function in Women With Polycystic Ovary Syndrome Completed NCT03252223 Phase 4 Recombinant Follicle Stimulating Hormone
7 The Effect of Metformin Added to Clomiphene Citrate on Pregnancy Rates in Hyperandrogenic, Chronic Oligoovulatory or Anovulatory Women: A Randomized Trial Completed NCT00413179 Phase 3 Metformin;Clomiphene citrate;Placebo
8 The Use of an MMP Inhibitor, Doxycycline, to Reduce Ovarian Androgen Production and Restore Normal Cycling in Women With Polycystic Ovarian Syndrome Completed NCT01788215 Phase 3 doxycycline
9 Comparison of Metformin and Pioglitazone in Regulating Menstrual Irregularities and Hyperandrogenism Unknown status NCT03757923 Phase 1, Phase 2 TAB METFORMIN;TAB PIOGLITAZONE
10 The Effect of Ibuprofen on the Endocrine and Metabolic Status of Women With PCOS. Unknown status NCT04485403 Phase 2 Ibuprofen
11 Is the Co-administration of Metformine and CC as Compared to Placebo and CC Superior to Induce Ovulation in PCOS Patients With a Confirmed insulin-resistant-a Double Blind Randomized Clinical Trial Unknown status NCT02523898 Phase 2 metformine;placebo;clomiphene citrate
12 Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women Completed NCT00704912 Phase 2 Orlistat/Meal Replacement/Lifestyle Modification;Loestrin 1/20;Combination of treatments
13 Phase II Randomized Study of Leuprolide Vs Oral Contraceptive Therapy Vs Leuprolide and Oral Contraceptive Therapy for Ovarian Hyperandrogenism Completed NCT00004763 Phase 2 leuprolide;Ethinyl estradiol/norethindrone
14 Phase II Study of the Effect of Leuprolide Acetate and Spironolactone on Insulin Resistance in Hyperandrogenic Women With Polycystic Ovarian Disease or Hyperandrogenism Insulin Resistance Acanthosis Nigricans Syndrome Completed NCT00004311 Phase 2 leuprolide acetate;spironolactone
15 Acupuncture or Metformin for Insulin Resistance in Women With Polycystic Ovary Syndrome: A Randomized Controlled Trial Recruiting NCT02647827 Phase 2 Metformin
16 Inositol Supplementation to Treat Polycystic Ovary Syndrome: A Double Blind Dose Ranging RCT (INSUPP-PCOS) Recruiting NCT03864068 Phase 2 Inositol
17 Androgen Excess as a Cause for Adipogenic Dysfunction in PCOS Women Recruiting NCT01889199 Phase 2 Flutamide
18 Suppression of Daytime and Nighttime LH Frequency by Progesterone in Early Pubertal Girls With and Without Hyperandrogenemia (JCM024) Recruiting NCT01428089 Phase 1 Progesterone;Placebo
19 Influence of Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome Unknown status NCT01569425
20 Influence of Meal Timing on Glucose Metabolism and Hyperandrogenism in Lean Women With Polycystic Ovary Syndrome Unknown status NCT01711476
21 Whole Genome Analysis for the Detection of Key Genes in the Polycystic Ovary Syndrome - a Study on Multigenerational Families Unknown status NCT00665171
22 Ultrasound Three-dimensional Characterization of Ovarian Morphology in Women With Polycystic Ovary Syndrome (PCOS) Unknown status NCT02402413
23 The Effect of Lactobacillus Rhamnosus Supplementation on Body Mass, Hyperandrogenism and Insulin Resistance in Overweight and Obese Polycystic Ovary Syndrome Women - Randomized Nutritional Study Completed NCT03902301
24 Clinical and Biochemical Presentations of Distinctive Types of Biochemical Hyperandrogenism in Premenopausal Taiwanese Women Completed NCT01940666
25 Obesity and Clinical Presentation of Hyperandrogenism Completed NCT01114633
26 A Study of Clinical Presentation and Cardiovascular Disease of Hyperandrogenism and Polycystic Ovary Syndrome in Obese and Non-obese Taiwanese Women Completed NCT01113918
27 Role of Insulin Action and Free Fatty Acids in Hyperandrogenism and Role of Metabolism of Inositols in Insulin Resistance of Women With Polycystic Ovary Syndrome Completed NCT01019356 Rosiglitazone;Acarbose
28 Effect of Free Fatty Acids on Androgen Precursors in Vivo in Healthy Young Women Completed NCT00473603 lipid/heparin infusion
29 Effects of Combined Therapy With Myo-inositol and Alpha-Lipoic Acid on Clinical, Endocrine and Metabolic Features in Women Affected by Polycystic Ovary Syndrome Completed NCT02651636 myo-inositol,alpha-lipoic acid and folic acid
30 Circulating Androgen Levels Are Not Affected by the Administration of Vaginal Micronized Progesterone for Withdrawal Bleeding in Patients With Polycystic Ovarian Syndrome Completed NCT03088046 Micronized Progesterone
31 Health-related Quality of Life, Sexuality and Hormone Status After Bariatric Surgery Completed NCT03188640
32 C Type Natriuretic Peptide and Polycystic Ovary Syndrome Completed NCT04006171
33 Effect of Decreasing Iron Tissue Depots on the Cardiovascular Risk of Women With Polycystic Ovary Syndrome Completed NCT02460445 ethinylestradiol;Cyproterone Acetate
34 Adrenal Hyperplasia Among Young Patients With Polycystic Ovarian Syndrome Completed NCT01313455
35 Effects of Oral Androgen Administration on Hyperglycemia-Induced Inflammation in Lean Reproductive-Age Women Completed NCT01753037
36 Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone in Hyperandrogenemic Adolescent Girls (JCM025) Completed NCT01427595 Metformin;Progesterone;estrace
37 Effect of Hyperandrogenism on IVF Success Rates in PCOS Patients Recruiting NCT05555680
38 Relative Contributions of Predictors of Hyperandrogenism in Older vs. Young Women With PCOS Recruiting NCT03905603 Early Phase 1 ACTH;rhCG
39 Study to Evaluate if Androgen-receptor Blockade (Spironolactone) Improves Progesterone-suppression of Wake Luteinizing Hormone Pulse Frequency in Pubertal Girls With Hyperandrogenism Recruiting NCT03068910 Early Phase 1 Micronized progesterone;Spironolactone;Placebo
40 Does Spironolactone Normalize Sleep-wake Luteinizing Hormone (LH) Pulse Frequency in Pubertal Girls With Hyperandrogenism? (CBS010) Recruiting NCT04723862 Early Phase 1 Spironolactone;Placebo
41 Study to Assess Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism Recruiting NCT00929006 Early Phase 1 Micronized progesterone suspension;Placebo
42 Effects of Myo-inositol on the Menstrual Cycle, Hyperandrogenism, Chronic Inflammatory Process and Carbohydrate Metabolism in Women With Polycystic Ovary Syndrome Recruiting NCT04892186 Myo-inositol;Metformin
43 Prevalence of Hyperandrogenism in Young Women With Type 1 Diabetes and Study of the Underlying Pathophysiological Mechanisms Recruiting NCT04979377
44 Health of Offspring Born to Mothers With Polycystic Ovary Syndrome in Guangzhou Cohort Study Recruiting NCT03742011
45 FEmale Metabolic Risk and Androgens: an Irish Longitudinal (FEMAIL) Study Recruiting NCT04912648
46 Metabolic Profile and Adipokine Levels in Young Hyperandrogenemic Females Recruiting NCT05112029
47 Ovarian Contribution to Androgen Production in Adolescent Girls Recruiting NCT01421810 Dexamethasone;rhCG
48 Assessment of Day-night Secretion of Progesterone and LH Across Pubertal Maturation in Girls With and Without Hyperandrogenemia (JCM023) Recruiting NCT02155933
49 Does Treatment of Androgen Excess Using Spironolactone Improve Ovulatory Rates in Girls With Androgen Excess? Recruiting NCT04075149 Early Phase 1 Spironolactone
50 Dissecting Androgen Excess and Metabolic Dysfunction for an Integrated Systems Approach to Polycystic Ovary Syndrome Through the Assessment of Detailed Phenome and Metabolome Data Recruiting NCT03911297

Search NIH Clinical Center for Hyperandrogenism

Cochrane evidence based reviews: hyperandrogenism

Genetic Tests for Hyperandrogenism

Anatomical Context for Hyperandrogenism

Organs/tissues related to Hyperandrogenism:

MalaCards : Ovary, Skin, Pituitary, Skeletal Muscle, Adrenal Cortex, Liver, Bone

Publications for Hyperandrogenism

Articles related to Hyperandrogenism:

(show top 50) (show all 4377)
# Title Authors PMID Year
1
Frequency of adiponectin gene polymorphisms in polycystic ovary syndrome and the association with serum adiponectin, androgen levels, insulin resistance and clinical parameters. 53 62
20388053 2010
2
Premature pubarche in Mediterranean girls: high prevalence of heterozygous CYP21 mutation carriers. 53 62
20059433 2010
3
[Polymorphism of CYP11A1 gene in Chinese patients with polycystic ovarian syndrome]. 53 62
20450755 2010
4
Detection and management of late-onset 21-hydroxylase deficiency in women with hyperandrogenism. 53 62
20070950 2010
5
Response of IGF and IL-6 to ovarian stimulation in PCOS and normal women. 53 62
19938957 2009
6
Association between CYP19 gene SNP rs2414096 polymorphism and polycystic ovary syndrome in Chinese women. 53 62
20015405 2009
7
[Increased level of prostate-specific antigen: a diagnostic marker of hyperandrogenism women]. 53 62
20218317 2009
8
Short-term metformin treatment for clomiphene citrate-resistant women with polycystic ovary syndrome. 53 62
19552904 2009
9
Body iron stores and glucose intolerance in premenopausal women: role of hyperandrogenism, insulin resistance, and genomic variants related to inflammation, oxidative stress, and iron metabolism. 53 62
19401444 2009
10
Genetic polymorphisms of GnRH and gonadotrophic hormone receptors affect the phenotype of polycystic ovary syndrome. 53 62
19403562 2009
11
Clomiphene citrate resistance in relation to follicle-stimulating hormone receptor Ser680Ser-polymorphism in polycystic ovary syndrome. 53 62
19401323 2009
12
KLF15 Is a transcriptional regulator of the human 17beta-hydroxysteroid dehydrogenase type 5 gene. A potential link between regulation of testosterone production and fat stores in women. 53 62
19366843 2009
13
The role of genetic variation in the lamin a/c gene in the etiology of polycystic ovary syndrome. 53 62
19401371 2009
14
A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. 53 62
18851710 2009
15
The frequency of CYP 21 gene mutations in Turkish women with hyperandrogenism. 53 62
19085698 2009
16
Effects of pioglitazone on menstrual frequency, hyperandrogenism and insulin resistance in adoloscents and young adults with polycystic ovary syndrome. 53 62
19345914 2009
17
Nonhuman primates as models for human adrenal androgen production: function and dysfunction. 53 62
18683055 2009
18
[Effect of anti-Müllerian hormone on P450 aromatase mRNA expression in cultured human luteinized granulose cells]. 53 62
19570444 2009
19
An association between non-alcoholic fatty liver disease and polycystic ovarian syndrome. 53 62
19215335 2009
20
Effects of growth hormone reduction in a patient with polycystic ovary syndrome complicated with acromegaly. 53 62
18840925 2009
21
Polycystic ovary syndrome: treatment strategies and management. 53 62
19013863 2008
22
Polycystic ovary syndrome: pathophysiology, molecular aspects and clinical implications. 53 62
19078868 2008
23
Clinical, endocrine, and metabolic effects of acarbose, a alpha-glucosidase inhibitor, in overweight and nonoverweight patients with polycystic ovarian syndrome. 53 62
18377903 2008
24
Insulin resistance, obesity, hypofibrinolysis, hyperandrogenism, and coronary heart disease risk factors in 25 pre-perimenarchal girls age < or =14 years, 13 with precocious puberty, 23 with a first-degree relative with polycystic ovary syndrome. 53 62
19209619 2008
25
Cardiovascular risk in women with polycystic ovary syndrome. 53 62
18799960 2008
26
Cardiometabolic abnormalities in the polycystic ovary syndrome: pharmacotherapeutic insights. 53 62
18602948 2008
27
Body shape and size and insulin resistance as early clinical predictors of hyperandrogenic anovulation in ethnic minority adolescent girls. 53 62
18639784 2008
28
Insulin receptor autoimmunity and insulin resistance. 53 62
18556968 2008
29
Differences in low-grade chronic inflammation and insulin resistance in women with previous gestational diabetes mellitus and women with polycystic ovary syndrome. 53 62
18382906 2008
30
Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome. 53 62
18362299 2008
31
Implications of polycystic ovary syndrome on oocyte development. 53 62
18181083 2008
32
Polycystic ovary syndrome and oocyte developmental competence. 53 62
18081939 2008
33
[Polymorphism in CYP11alpha and CYP17 genes and the etiology of hyperandrogenism in patients with polycystic ovary syndrome]. 53 62
18499961 2008
34
Recent advances in diagnosis, treatment, and outcome of congenital adrenal hyperplasia due to 21-hydroxylase deficiency. 53 62
17885806 2007
35
Hormonal profile in women with polycystic ovarian syndrome with or without type 1 diabetes mellitus. 53 62
17895317 2007
36
Hyperandrogenism, mediated by obesity and receptor polymorphisms, promotes aggressive epithelial ovarian cancer biology. 53 62
17825390 2007
37
Metformin improves polycystic ovary syndrome symptoms irrespective of pre-treatment insulin resistance. 53 62
17984248 2007
38
Novel endocrine disrupter effects of classic and atypical antipsychotic agents and divalproex: induction of adrenal hyperandrogenism, reversible with metformin or rosiglitazone. 53 62
17954415 2007
39
Neuroendocrine effects of androgens in adult polycystic ovary syndrome and female puberty. 53 62
17710731 2007
40
Phenotypic characteristics according to insulin sensitivity in non-obese Korean women with polycystic ovary syndrome. 53 62
17606307 2007
41
Association of the GAA1013-->GAG polymorphism of the insulin-like growth factor-1 receptor (IGF1R) gene with premature pubarche. 53 62
17442315 2007
42
Serum visfatin in relation to insulin resistance and markers of hyperandrogenism in lean and obese women with polycystic ovary syndrome. 53 62
17582143 2007
43
Insulin-like factor 3: a new circulating hormone related to luteinizing hormone-dependent ovarian hyperandrogenism in the polycystic ovary syndrome. 53 62
17356050 2007
44
Interactions among peroxisome proliferator activated receptor-gamma, insulin signaling pathways, and steroidogenic acute regulatory protein in human ovarian cells. 53 62
17374711 2007
45
Lack of association between common polymorphisms in the 17beta-hydroxysteroid dehydrogenase type V gene (HSD17B5) and precocious pubarche. 53 62
17583494 2007
46
Pioglitazone inhibits androgen production in NCI-H295R cells by regulating gene expression of CYP17 and HSD3B2. 53 62
17138841 2007
47
Low-dose glucocorticoids in hyperandrogenism. 53 62
17628912 2007
48
Childhood obesity and insulin resistance. 53 62
17709876 2007
49
Current approaches to the diagnosis and treatment of polycystic ovarian syndrome in youth. 53 62
17426408 2007
50
Obesity and insulin resistance but not hyperandrogenism mediates vascular dysfunction in women with polycystic ovary syndrome. 53 62
17067587 2006

Variations for Hyperandrogenism

Expression for Hyperandrogenism

Search GEO for disease gene expression data for Hyperandrogenism.

Pathways for Hyperandrogenism

Pathways related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 21)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.69 ADIPOQ CYP11A1 CYP17A1 CYP19A1 CYP21A2 HSD11B1
2
Show member pathways
12.62 POMC CYP21A2 CYP19A1 CYP17A1 CYP11A1
3
Show member pathways
12.59 POMC CYP21A2 CYP19A1 CYP17A1 CYP11A1
4 12.24 ADIPOQ CYP11A1 CYP17A1 CYP19A1 IGFBP1 IGFBP3
5
Show member pathways
12.17 SRD5A1 POMC INS HSD3B2 HSD11B1 CYP21A2
6
Show member pathways
11.94 WNT4 SRD5A1 IGF1 AR
7 11.8 INS IGFBP3 IGF1
8 11.72 CYP11A1 CYP21A2 HSD3B2 POMC
9
Show member pathways
11.66 PRL HSD11B1 CYP11A1
10 11.63 WNT4 INS IGFBP3 IGF1 ADIPOQ
11 11.52 POMC INS GNRH1
12
Show member pathways
11.46 HSD3B2 CYP19A1 CYP17A1
13 11.36 PRL INSR INS
14 11.35 INSR INS ADIPOQ
15 11.32 IGF1 CYP19A1 AR
16
Show member pathways
11.21 SRD5A1 POMC HSD3B2 HSD11B1 CYP21A2 CYP19A1
17 11.15 CYP21A2 CYP19A1 CYP17A1 CYP11A1
18 10.91 PRL POMC INS
19 10.84 SHBG GNRH1 AR
20 10.59 HSD3B2 CYP17A1 CYP11A1
21
Show member pathways
10.49 HSD3B2 CYP11A1

GO Terms for Hyperandrogenism

Cellular components related to Hyperandrogenism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 insulin-like growth factor ternary complex GO:0042567 9.26 IGFBP3 IGF1
2 insulin-like growth factor binding protein complex GO:0016942 8.92 IGFBP3 IGF1

Biological processes related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 glucose homeostasis GO:0042593 10.18 POMC INSR INS ADIPOQ
2 male gonad development GO:0008584 10.17 AR INSR SRD5A1 WNT4
3 cellular response to insulin stimulus GO:0032869 10.14 ADIPOQ CAPN10 INSR SRD5A1
4 positive regulation of MAPK cascade GO:0043410 10.13 INSR INS IGFBP3 IGF1 AR
5 positive regulation of mitotic nuclear division GO:0045840 10.03 INSR INS IGF1
6 activation of protein kinase B activity GO:0032148 10.02 INSR INS IGF1
7 lipid metabolic process GO:0006629 10 SRD5A1 HSD3B2 HSD11B1 CYP21A2 CYP19A1 CYP17A1
8 sterol metabolic process GO:0016125 9.99 CYP21A2 CYP19A1 CYP11A1
9 positive regulation of glycolytic process GO:0045821 9.95 IGF1 INS INSR
10 prostate gland growth GO:0060736 9.92 CYP19A1 AR
11 regulation of insulin-like growth factor receptor signaling pathway GO:0043567 9.91 IGFBP3 IGFBP1
12 positive regulation of respiratory burst GO:0060267 9.91 INSR INS
13 female genitalia development GO:0030540 9.9 SRD5A1 CYP19A1
14 androgen catabolic process GO:0006710 9.88 SRD5A1 CYP19A1
15 positive regulation of glycogen biosynthetic process GO:0045725 9.88 INSR INS IGF1
16 positive regulation of insulin-like growth factor receptor signaling pathway GO:0043568 9.85 IGFBP3 IGF1 AR
17 tertiary branching involved in mammary gland duct morphogenesis GO:0060748 9.83 WNT4 AR
18 sex differentiation GO:0007548 9.8 WNT4 SRD5A1 CYP17A1
19 androgen biosynthetic process GO:0006702 9.8 CYP17A1 HSD3B2 SRD5A1
20 steroid metabolic process GO:0008202 9.8 SRD5A1 HSD11B1 CYP21A2 CYP17A1 CYP11A1
21 C21-steroid hormone metabolic process GO:0008207 9.77 HSD3B2 CYP11A1
22 positive regulation of glucose import GO:0046326 9.65 INSR INS IGF1 CAPN10 ADIPOQ
23 glucocorticoid biosynthetic process GO:0006704 9.63 CYP21A2 CYP17A1 CYP11A1
24 steroid biosynthetic process GO:0006694 9.36 SRD5A1 HSD3B2 CYP21A2 CYP19A1 CYP17A1 CYP11A1

Molecular functions related to Hyperandrogenism according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 10.1 CYP21A2 CYP19A1 CYP17A1 CYP11A1
2 iron ion binding GO:0005506 10.08 CYP21A2 CYP19A1 CYP17A1 CYP11A1
3 oxidoreductase activity GO:0016491 9.97 CYP11A1 CYP17A1 CYP19A1 CYP21A2 HSD11B1 HSD3B2
4 insulin-like growth factor receptor binding GO:0005159 9.88 INSR INS IGF1
5 insulin-like growth factor I binding GO:0031994 9.85 INSR IGFBP3 IGFBP1
6 androgen binding GO:0005497 9.76 SHBG AR
7 monooxygenase activity GO:0004497 9.73 CYP21A2 CYP19A1 CYP17A1 CYP11A1
8 insulin-like growth factor II binding GO:0031995 9.63 INSR IGFBP3 IGFBP1
9 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.56 CYP21A2 CYP19A1 CYP17A1 CYP11A1
10 steroid binding GO:0005496 9.56 SHBG HSD11B1 CYP21A2 AR
11 hormone activity GO:0005179 9.4 PRL POMC INS IGF1 GNRH1 ADIPOQ

Sources for Hyperandrogenism

2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....